Claudio Dazzi

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo et al. · Clinical Cancer Research · 2019 · 186 citations · Full text

Medicine, Oncology, Pharmacology +16

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Marcello Tiseo, Luca Boni, Francesca Ambrosio et al. · Journal of Clinical Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacotherapy +12

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

Paola Ulivi, Elisa Chiadini, Claudio Dazzi et al. · Clinical Lung Cancer · 2015 · 89 citations

Medicine, Molecular Genetics, Oncology +14

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11